Analyst consensus rating
Immunic Analyst Rating: Strong Buy
IMUX is rated Strong Buy by 11 analysts with a $42.18 target. As of 2026-09-02.
Direct answer
Immunic's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $42.18.
Forecast evidence checked September 2, 2026.
Get free Immunic email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $14.58
- Average price target
- $42.18
- High price target
- $85.00
- Low price target
- $19.00
- Low target gap
- +30.3%
- Target upside
- +189.3%
- High target gap
- +483%
- Target range width
- 452.7%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immunic?
Immunic has a verified Strong Buy consensus. The same dataset has an average price target of $42.18.
How far are Immunic's low and high targets from the recorded price?
The low target implies +30.3%, while the high target implies +483%.
How many analysts are included in Immunic's consensus?
The verified consensus includes 11 analysts.
How is Immunic's target upside or downside calculated?
The average target of $42.18 is divided by the recorded price of $14.58, then one is subtracted to produce +189.3%. This does not guarantee a future return.
When was Immunic's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.